Thirst in End-Stage Liver Disease: From Symptom Disregard to a Multidisciplinary Clinical Pathway and Future Perspectives: A Narrative Review Authors: Min Xu, Shuhui Yang, Siyan Guo, Junwei Su, Xiaoxin Wu Published: 2026 ABSTRACT PurposeThirst is a common but clinically under-recognized symptom among patients with end-stage liver disease (ESLD) and may adversely affect comfort, nutritional intake, treatment adherence, and quality of life. This review aimed to systematically elucidate the pathogenesis, clinical management dilemmas, and limitations of current interventions, while highlighting the need for population-specific assessment tools and an integrated management framework.MethodsA narrative review was based on a structured literature search of PubMed, Web of Science, CINAHL, and Scopus from database inception through December 2025. Original studies, reviews, and clinical guidelines addressing thirst, dry mouth, symptoms, and fluid management in ESLD were included, and the evidence was synthesized thematically.ResultsThirst in ESLD results from interactions among liver failure, portal hypertension, diuretic and vasopressin V2 receptor antagonist use, electrolyte disturbances, and salivary dysfunction. Four major clinical dilemmas were identified: (i) Fluid restriction for ascites may aggravate thirst; (ii) diuretics are essential for controlling ascites but may intensify symptoms; (iii) hyponatremia management requires careful fluid regulation despite thirst aggravated by reduced effective arterial blood volume, neurohumoral activation, diuretic exposure, oral dryness, and fluid restriction; (iv) hepatogenous diabetes and salivary dysfunction may further contribute to persistent dry mouth and thirst. Current assessment strategies rely on non-specific tools including the Numerical Rating Scale (NRS) and Thirst Distress Scale (TDS), because no ESLD-specific instrument exists. Non-pharmacological interventions, such as ice-cold water spray and mint ice cubes, are promising but require validation in ESLD-specific clinical trials.ConclusionThirst in ESLD is a multifactorial and distressing symptom that remains inadequately managed. We propose a “4S” integrated management framework (Screening, Scoring, Stratification, and Stepped care) to guide clinical practice. Future research should prioritize mechanism-driven human studies, randomized controlled trials evaluating targeted interventions, and the development of an ESLD-specific thirst assessment scale. Introduction End-Stage liver disease (ESLD) is a major contributor to global morbidity and mortality. It represents the final common pathway of multiple chronic liver diseases. Liver disease currently accounts for approximately 2 million deaths annually worldwide, with cirrhosis and its complications representing a substantial proportion of liver-related mortality.1 The quality of life of patients with ESLD is profoundly impaired. Recently, as palliative and supportive care concepts have been increasingly integrated into hepatology, symptom management has gradually moved from the periphery to the center of clinical attention. The 2022 American Association for the Study of Liver Diseases practice guidance explicitly emphasizes the importance of symptom management and palliative care in decompensated cirrhosis and highlights patient-reported outcomes as an important measure of treatment response and disease burden.2 In this review, ESLD mainly refers to decompensated cirrhosis and advanced cirrhosis requiring symptom-oriented management. Despite this shift, thirst—an apparently simple but often distressing symptom—remains largely outside the clinical focus of routine hepatology practice. Thirst is among the most prevalent, intense, and distressing symptoms reported by ICU patients.3–9 However, it is rarely assessed systematically in liver disease care. Dry mouth and other nutrition-impact symptoms are common in patients with chronic liver disease and are associated with malnutrition, psychological distress, and increased healthcare utilization.10–17 Nevertheless, no clinical guideline or expert consensus specifically addresses thirst management in ESLD.2,18 As a result, clinical practice relies largely on empirical measures rather than a structured, evidence-informed approach. This review aims to summarize epidemiology, pathogenesis, assessment methods, and management strategies for thirst in ESLD and propose an integrated management framework to guide clinical practice and future research. Methods Search Strategy We conducted a structured, narrative literature search across PubMed/MEDLINE, Web of Science, CINAHL, and Scopus from database inception to December 2025. Search terms were used in various combinations. They include “ESLD”, “cirrhosis”, “thirst”, “xerostomia”, “dry mouth”, “symptom management”, “multidisciplinary care”, “diuretics”, “tolvaptan”, “hyponatremia”, and “quality of life”. We prioritized English-language publications. Chinese-language studies were also considered when they directly addressed thirst, dry mouth, symptom assessment, or nursing interventions relevant to patients with cirrhosis or ESLD. We manually screened the reference lists of included articles and relevant reviews for additional studies. Inclusion and Exclusion Criteria We included original research, such as cross-sectional, cohort, case–control, and randomized controlled trials, as well as systematic reviews, meta-analyses, and clinical guidelines that addressed thirst, dry mouth, or related fluid and symptom management in adult patients aged ≥18 years with ESLD or decompensated cirrhosis. Studies focusing exclusively on acute liver failure or post-liver transplant patients were excluded. Besides, case reports, conference abstracts, and editorials were excluded. Study Selection and Data Extraction Due to the narrative nature of the review, no formal risk-of-bias assessment was performed. Data extracted included study characteristics (author, year, country, and design), population details, thirst assessment methods, prevalence, mechanisms, interventions, and key findings. Results Epidemiology of Thirst in ESLD Thirst and dry mouth are common in chronic liver disease, although ESLD-specific epidemiological data remain limited. In a cross-sectional study of 133 patients with chronic liver disease, Lindqvist et al reported that 120/133 patients (90%) exhibited at least one nutrition impact symptom, with dry mouth being the most frequent 81/133 (61%). Notably, 68/133 (51%) reported four or more such symptoms, and symptom number was significantly associated with malnutrition (P = 0.004) and reduced health-related quality of life (P < 0.001).11 Thirst has also been reported in patients with Child-Pugh class A cirrhosis and appears to be more pronounced in patients undergoing liver transplant evaluation,19,20 likely due to more advanced decompensation and aggressive diuretic use.11,21,22 Beyond discomfort, thirst may complicate clinical management and worsen patient-reported outcomes, which are increasingly recognized as important measures of treatment response and disease burden. Severe thirst may undermine adherence to prescribed fluid restriction and complicate the management of ascites or severe hyponatremia.21,23 Furthermore, thirst-related discomfort may evoke anxiety and feelings of helplessness.24 Depression has also been independently associated with frequent thirst in patients with heart failure.25,26 Whether this relationship applies to ESLD is unknown.12,13,15 In ICU patients, persistent intense thirst lasting more than 24 h was associated with a 4.95-fold higher risk of delirium.27 This finding may be clinically relevant for patients with ESLD, who are already vulnerable to hepatic encephalopathy.28 Pathogenesis of Thirst in ESLD The mechanisms underlying thirst in ESLD are multifactorial, involving osmotic, volumetric, drug-induced, metabolic, and salivary factors that interact within a complex neurohumoral network (Figure 1). Figure 1Proposed mechanisms and clinical consequences of thirst and dry mouth in ESLD. Bold text indicates key pathophysiological factors and clinical consequences. Solid arrows, including downward arrows, indicate the proposed direction of influence, whereas dotted lines indicate indirect or contributory relationships. ↑ and ↓ indicate increased and decreased levels or activity, respectively; icons are illustrative only.The diagram outlines mechanisms and effects of thirst and dry mouth in end-stage liver disease (ESLD), divided into triggers, pathways and consequences. Triggers include portal hypertension, ascites, reduced arterial blood volume, hepatorenal dysfunction, hyponatremia, diuretic and vaptan exposure and salivary issues. These affect neurohumoral pathways like RAAS activation, vasopressin release and osmotic imbalance. Angiotensin II impacts brain regions, stimulating thirst. The hypothalamus processes signals, increasing thirst perception. Consequences involve excessive fluid intake, poor fluid restriction adherence, anxiety, depression, malnutrition, reduced life quality, hospital readmission and higher healthcare use. Solid arrows show direct effects; dotted lines indicate indirect ones.ESLD triggers, thirst pathways and clinical effects: interactions and influences diagram.Abbreviations: ESLD, End-Stage liver disease; ECV, effective circulating volume; RAAS, renin–angiotensin–aldosterone system; Ang II, angiotensin II; AVP, Arginine Vasopressin; V2, vasopressin V2 receptor; SFO, subfornical organ; OVLT, organum vasculosum of the lamina terminalis; Na⁺, sodium. Proposed mechanisms and clinical consequences of thirst and dry mouth in ESLD. Bold text indicates key pathophysiological factors and clinical consequences. Solid arrows, including downward arrows, indicate the proposed direction of influence, whereas dotted lines indicate indirect or contributory relationships. ↑ and ↓ indicate increased and decreased levels or activity, respectively; icons are illustrative only. Osmotic and Neurohumoral Dysregulation In cirrhosis, reduced effective arterial blood volume promotes non-osmotic vasopressin release and activation of the renin-angiotensin-aldosterone system (RAAS). This contributes to water retention, altered sodium handling, and thirst-related neurohumoral activation.21,28–31 However, in patients with hyponatremia, thirst is unlikely to be directly driven by hypo-osmolality. Instead, it may reflect reduced effective arterial blood volume, RAAS activation, non-osmotic vasopressin release, diuretic-related volume depletion, dry mouth, and the discomfort caused by fluid restriction. Accordingly, dilutional hyponatremia should be considered a marker of advanced circulatory and neurohumoral dysregulation rather than a direct osmotic trigger for thirst.21,28,32,33 Copeptin, a stable surrogate marker of arginine vasopressin release, may reflect osmotic and hemodynamic activation relevant to thirst, although it is not itself considered a direct mediator of thirst.34,35 B-type natriuretic peptide (BNP) promotes natriuresis and vasodilation and may counter-regulate the RAAS; experimental evidence suggests that it can attenuate angiotensin II–induced drinking.36,37 Hypovolemic Thirst Tense ascites increases intra-abdominal pressure and reduces effective circulating volume, thereby activating the RAAS.21,33 The subfornical organ (SFO) is a sensory circumventricular organ located in the midline along the anterodorsal wall of the third ventricle, immediately beneath the fornix and near the interventricular foramina (foramina of Monro).30,38,39 Unlike most brain regions, the SFO lacks a complete conventional blood–brain barrier, allowing circulating signals such as angiotensin II to access and activate local neurons.38–40 Angiotensin II not only induces vasoconstriction but also stimulates thirst by activating type 1 angiotensin receptors in the SFO.31,38 This pathway represents a key mechanism of “hypovolemic thirst” in ESLD. Drug-Induced Thirst Loop diuretics such as furosemide may cause excessive water and sodium loss, leading to activation of the RAAS and indirectly intensifying thirst.22,23 Vasopressin V2 receptor antagonists (vaptans), which are used in hyponatremia management in cirrhosis, can also cause thirst. In the randomized trial by Ginès et al, thirst occurred in 10/35 (28.6%) and 10/38 (26.3%) of patients receiving satavaptan 12.5 mg/day and 25 mg/day, respectively, compared with 2/35 (5.7%) on placebo.41 Similarly, in a Chinese Phase II trial of tolvaptan for cirrhotic ascites, the most common adverse events were dry mouth and thirst, with incidences ranging from 8/57 (14.0%) to 16/63 (25.4%) and 17/57 (29.8%) to 20/63 (31.7%), respectively.42 Metabolic and Endocrine Factors Hepatogenous diabetes may lead to hyperglycemia, osmotic diuresis, and water loss, thereby stimulating thirst.43 In addition, oral dryness and salivary dysfunction may contribute to a “dry mouth–thirst” cycle in patients with chronic liver disease.11,44 Salivary dysfunction in ESLD is likely multifactorial. Evidence from alcoholic cirrhosis suggests that metabolic derangements and structural changes in the parotid gland, including fatty infiltration, edema, and fibrosis, may impair salivary secretion.45 Diuretic exposure can further reduce salivary flow and alter salivary composition, while hepatogenous diabetes and other xerogenic medications may aggravate oral dryness.43,46–48 ESLD may contribute to thirst through multiple interacting pathways, including reduced effective arterial blood volume, RAAS activation, non-osmotic vasopressin release, fluid restriction, diuretic and vaptan exposure, hyperglycemia-related osmotic diuresis, and salivary dysfunction. These mechanisms may act synergistically and result in thirst distress, poor adherence to fluid restriction, psychological burden, reduced quality of life, and increased healthcare use.11–15,21,23–28,43–48 Assessment of Thirst in ESLD Currently, there is no gold standard tool for assessing thirst in ESLD. The Numerical Rating Scale (NRS, 0–10) is most commonly used due to its simplicity.49,50 The Visual Analogue Scale (VAS) may be more sensitive but requires greater patient cooperation.49,50 The Thirst Distress Scale (TDS) captures the psychological distress associated with thirst; the Chinese version has demonstrated good reliability (Cronbach’s α = 0.918) in patients receiving peritoneal dialysis.26,51 However, its validity in ESLD has not been established. The frequency and severity of dry mouth were measured using the Xerostomia Inventory (XI).44 Objective measures include unstimulated salivary flow rate (USFR) and clinical oral examination. A resting salivary flow rate below 0.1 mL/min is commonly considered indicative of salivary gland hypofunction; however, disease-specific reference values for ESLD remain unavailable.52–54 We propose a comprehensive assessment framework comprising: (1) routine assessment of thirst intensity using NRS or VAS; (2) evaluation of thirst-related distress using the TDS; (3) oral moisture examination; (4) laboratory tests, including serum sodium, glucose, and renal function; (5) review of diuretic and vaptan exposure. Patients with ESLD commonly have multimorbidity, particularly diabetes mellitus, chronic kidney disease, and cardiovascular disease.55 Thirst assessment should therefore extend beyond liver-directed therapy to medications used for coexisting conditions. Polypharmacy and medication-related problems are frequent in decompensated cirrhosis,56 while anticholinergic agents, antidepressants, opioids, and some cardiovascular or respiratory medications may reduce salivary function or aggravate xerostomia.48,57 A structured medication review should consider indication, dose, timing, recent changes, and cumulative xerogenic or volume-depleting effects, preferably with pharmacist input; clinically necessary treatment should not be stopped solely because thirst is present.56,57 Current Management Dilemmas Four core clinical tensions, summarized in Table 1, make thirst management particularly challenging in ESLD. Table 1Core Clinical Dilemmas in Thirst Management in Patients with ESLDClinical ScenariosMechanisms Contributing to ThirstClinical ChallengesPotential Management ConsiderationsFluid restriction for ascitesRestricted water intake increases thirst perception21,23,33Poor adherence to fluid restrictionIndividualized fluid targets and oral careDiuretic therapyVolume depletion and RAAS activation21,22Worsening thirst distressUse the lowest effective diuretic doseHyponatremiaNon-osmotic antidiuretic hormone (ADH) activation and neurohumoral dysregulation21,28,32,33Difficulty balancing sodium correction and symptom reliefCareful sodium monitoring and symptom-guided managementHepatogenous diabetesHyperglycemia-induced osmotic diuresis43,47Persistent dry mouth and thirstOptimized glycemic control and hydration assessment Table 1Core Clinical Dilemmas in Thirst Management in Patients with ESLDClinical ScenariosMechanisms Contributing to ThirstClinical ChallengesPotential Management ConsiderationsFluid restriction for ascitesRestricted water intake increases thirst perception21,23,33Poor adherence to fluid restrictionIndividualized fluid targets and oral careDiuretic therapyVolume depletion and RAAS activation21,22Worsening thirst distressUse the lowest effective diuretic doseHyponatremiaNon-osmotic antidiuretic hormone (ADH) activation and neurohumoral dysregulation21,28,32,33Difficulty balancing sodium correction and symptom reliefCareful sodium monitoring and symptom-guided managementHepatogenous diabetesHyperglycemia-induced osmotic diuresis43,47Persistent dry mouth and thirstOptimized glycemic control and hydration assessment Core Clinical Dilemmas in Thirst Management in Patients with ESLD Management Strategies Optimization of Pharmacotherapy Diuretics should be used at the lowest effective dose, preferably as a spironolactone-furosemide combination rather than a high-dose therapy. Monitoring the urine sodium/potassium ratio may help guide dose adjustments.21,22 Vaptans should be reserved for strict clinical indications. During vaptan therapy, fluid intake and serum sodium should be closely monitored, and overly restrictive fluid intake should be avoided when clinically inappropriate.32,33,41 Tolvaptan should be initiated at a low dose and titrated based on serum sodium levels and clinical response.42 Non-Pharmacological Interventions Evidence from ICU and palliative care populations suggests that non-pharmacological interventions are low-cost and potentially feasible. However, their efficacy and safety require validation in patients with ESLD.49,58,59 Ice-cold water spray using 0–4 °C sterile water applied to the soft palate, buccal mucosa, and tongue dorsum every 2–4 h significantly reduced thirst intensity in ICU patients.58 Mint ice cubes (1 cm3) reduced thirst intensity from 8.5 to 4.0 within 5 min (P < 0.001) in a pilot study of severely dehydrated patients.60,61 Traditional Chinese medicine approaches, such as acupressure at specific points (Lianquan CV23, Shuiquan KI5) and liquorice or dark plum sprays, have revealed some potential benefits; however, stronger evidence in patients with ESLD is required.62 Nutrition and Fluid Management Strict water restriction is not required for all patients with ESLD. In patients with serum sodium > 125 mmol/L, a more liberal fluid intake may be considered, depending on ascites severity, renal function, and overall volume status. For patients with serum sodium < 125 mmol/L, stricter fluid restriction should be implemented alongside intensified oral care and psychological support.21,33 In heart failure populations, combined sodium and fluid management strategies are associated with reduced thirst intensity. However, whether similar benefits apply to patients with ESLD remains uncertain and requires further investigation.63,64 For patients with ESLD, practical late-evening snacks may include a rice ball or bread accompanied by milk, yogurt, or soy milk, or a BCAA-enriched oral nutritional supplement. These options should be individualized according to glucose tolerance, volume status, renal function, and overall daily energy and protein requirements.65,66 Their potential effect on thirst is likely indirect and remains to be confirmed in ESLD-specific studies.65,66 The “4S” Integrated Management Framework We propose the stepwise clinical pathway illustrated in Figure 2. Figure 2The “4S” integrated management framework for thirst in patients with ESLD. The framework comprises four sequential components: screening, scoring, stratification, and stepped care. These labels indicate procedural steps rather than separate figure panels. Bold text indicates key assessment items, severity criteria, interventions, outcome goals, and multidisciplinary roles. Solid arrows indicate the sequence and direction of the 4S pathway; colors distinguish the four stages and severity categories. Icons are illustrative only. The Thirst Distress Scale (TDS) was originally developed for evaluating thirst.The 4S framework for managing thirst in ESLD patients includes Screening, Scoring, Stratification and Stepped care. Screening involves nurses assessing thirst (NRS 0 to 10), mouth moisture and fluid intake. Scoring evaluates thirst intensity using the Thirst Distress Scale (TDS), oral health, lab results, medications, psychological state and nutrition. Stratification classifies thirst as Mild (NRS 3, TDS less than 10), Moderate (NRS 4 to 6, TDS 10 to 18), or Severe (NRS 7, TDS greater than 18). Stepped care offers interventions: Mild involves education and fluid management; Moderate includes ice chips and medication review; Severe involves pharmacologic options and palliative care. Goals are reducing thirst, improving adherence, enhancing life quality and minimizing complications. A multidisciplinary team includes nursing, hepatology, pharmacy, nutrition, psychology and palliative care.Stratification classifies thirst as Mild (NRS less than equal to 3 and TDS less than 10), Moderate (NRS 4 to 6 or TDS 10 to 18), or Severe (NRS greater than equal to 7 or TDS greater than18).Abbreviations: ESLD, End-Stage liver disease; NRS, Numerical Rating Scale; TDS, Thirst Distress Scale. The “4S” integrated management framework for thirst in patients with ESLD. The framework comprises four sequential components: screening, scoring, stratification, and stepped care. These labels indicate procedural steps rather than separate figure panels. Bold text indicates key assessment items, severity criteria, interventions, outcome goals, and multidisciplinary roles. Solid arrows indicate the sequence and direction of the 4S pathway; colors distinguish the four stages and severity categories. Icons are illustrative only. The Thirst Distress Scale (TDS) was originally developed for evaluating thirst. Summary of Evidence Gaps Our synthesis identified several major knowledge gaps: (i) No randomized controlled trials have evaluated a thirst intervention exclusively in patients with ESLD; (ii) no disease-specific thirst assessment tool has been developed or validated for cirrhosis; (iii) the comparative effectiveness of different fluid restriction protocols (liberal versus restricted) on thirst and ascites control remains unknown; (iv) The relationships among RAAS activation, circulating angiotensin II, volume status, and patient-reported thirst remain insufficiently characterized in ESLD. In addition, the contribution of CLD-related complications and diuretic-associated adverse effects to thirst remains insufficiently defined. Future studies should clarify how ascites, hyponatremia, renal dysfunction, and diuretic-related volume depletion or electrolyte disturbances influence thirst severity and patient-reported outcomes.21,33,56 Discussion Summary of Principal Findings This review identifies thirst and dry mouth as significant, under-recognized symptoms in patients with ESLD. Available evidence indicates a substantial symptom burden, multifactorial mechanisms, and several management dilemmas. However, current evidence remains largely descriptive, and intervention studies specifically in ESLD populations are scarce. The proposed “4S” framework provides a practical, stepwise approach for integrating thirst management into routine hepatology care. Interpretation and Comparison with Existing Literature The mechanisms underlying thirst in ESLD parallel those described in heart failure, where thirst is similarly driven by RAAS activation, diuretic therapy, and fluid restriction.23,25,63,67 However, patients with ESLD have several distinctive features. Portal hypertension and ascites create a unique combination of reduced effective circulating volume and dilutional hyponatremia, while using vaptans introduces an additional iatrogenic thirst component.41,42 The lack of disease-specific assessment tools remains a major gap. Existing scales were developed mainly for heart failure, ICU populations, and have not been validated in the metabolic and fluid environment of cirrhosis.26,44,49–51 Non-pharmacological interventions, including ice spray and mint ice cubes, have demonstrated efficacy in ICU and palliative care settings and may be feasible for patients with ESLD.58–61 However, safety considerations are particularly important in this population, including aspiration risk, impaired consciousness, thrombocytopenia-related oral mucosal bleeding, and unstable sodium and volume status.2,21,33,68 The absence of randomized controlled trials evaluating thirst-specific interventions in ESLD underscores the urgent need for targeted clinical research. Implications for Multidisciplinary Practice Managing thirst in ESLD requires a structured, multidisciplinary approach to navigate complex fluid and medication. Hepatologists are responsible for adjusting diuretics and vaptans; nurses perform daily symptom assessments and oral care; dietitians individualize fluid, sodium, and nutritional prescriptions. Pharmacists review drug-related thirst; palliative care specialists address refractory thirst distress; dentists or oral medicine specialists manage salivary dysfunction. The “4S” framework operationalizes this teamwork by defining clear roles for each discipline at each step (Figure 2). Without such a multidisciplinary approach, the clinical dilemmas described in Table 1 are unlikely to be resolved effectively. Multidisciplinary Statement This review integrates evidence from hepatology, nursing, clinical pharmacology, nutrition, and palliative care. The pathophysiology, assessment, and management of thirst in ESLD are complex. They involve multiple organ systems: Renal, endocrine, neurological, and oral health systems. A multidisciplinary team comprising hepatologists, nurses, dietitians, pharmacists, and palliative care specialists is essential for implementing the proposed 4S framework and addressing a symptom that remains disregarded in routine clinical practice. Limitations of the Review The review has several limitations. First, due to the scarcity of high-quality primary studies in ESLD, we performed a narrative rather than a systematic review, and formal meta-analysis was not possible. Second, most included studies were cross-sectional and therefore subject to selection and recall bias.11,19 Third, although English- and Chinese-language publications were considered, the search strategy was mainly based on international databases, and Chinese databases such as CNKI, Wanfang, VIP, or SinoMed were not systematically searched. Consequently, relevant Chinese-language studies may have been missed, introducing potential database and language selection bias. Fourth, heterogeneity in thirst assessment methods across studies limited direct comparison of findings. Finally, because no intervention studies were available specifically in ESLD, management considerations are largely extrapolated from ICU, palliative care, heart failure, and dialysis populations.23,26,49,51,58–61,63,67,68 Future Research Directions Basic Research Human neuroimaging studies, including functional MRI, are needed to map thirst-related brain activity in regions such as SFO, OVLT (Organum vasculosum of the lamina terminalis), and anterior cingulate cortex in patients with ESLD.29–31,38–40,69–71 Biomarker studies should explore copeptin, angiotensin II, and brain natriuretic peptide as potential correlates of thirst intensity.34–37,69 The gut-liver-brain axis and its role in thirst regulation represent emerging areas of investigation.29,70,71 Clinical Research There is an urgent need for randomized controlled trials comparing different fluid restriction strategies. These trials should include non-pharmacological interventions for ESLD, such as ice sprays and mint ice cubes. Furthermore, they should assess diuretic optimization strategies, including sequential versus combined diuretic strategies, by using thirst-related outcomes as endpoints.21,22,58–61,64,67 Additionally, we must address a critical measurement gap in ESLD care. Developing and validating an ESLD-specific Cirrhosis Thirst Scale using either classical test theory or item response theory will be vital in assessing patients’ symptoms.18,26,51 Implementation Science Implementation studies should focus on integrating thirst assessment into daily nursing routines, developing evidence-informed clinical pathways, and training hepatology staff to recognize and manage thirst effectively. Establishing structured collaborations between hepatology and palliative care partnerships embeds symptoms-focused care into ESLD management. This approach enhances patient-centered and multidisciplinary care for patients with ESLD.2,72–75 Conclusions, Implications of the Study and Directions for Future Research Thirst is a prevalent, distressing, and clinically disregarded symptom in patients with end-stage liver disease. Its pathogenesis is multifactorial, involving osmotic, volumetric, drug-induced, metabolic, and salivary mechanisms. Current clinical practice is characterized by insufficient recognition, lack of standardized assessment, and fragmented interventions. The proposed “4S” integrated management framework (Screening, Scoring, Stratification, and Stepped care) provides a practical, multidisciplinary pathway to move from disregard to active management. High-quality basic and clinical research – including human mechanistic studies, randomized controlled trials of interventions, and development of a disease-specific thirst scale– is urgently needed to improve supportive care, symptom control, and patient-reported outcomes in ESLD.